Sequential Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapy and Late-Line Tucatinib in Patients With HER2-Positive Breast Cancer and Brain Metastases: A Real-World Case Report.
- DOI
- 10.7759/cureus.117705
- Published
- 2026 Oct
- Container
- Cureus
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.7759/cureus.117705,
title = {Sequential Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapy and Late-Line Tucatinib in Patients With HER2-Positive Breast Cancer and Brain Metastases: A Real-World Case Report.},
author = {Thakur P and Gupta M and Kant LC and Mehta P and Thummar V},
year = {2026},
journal = {Cureus},
doi = {10.7759/cureus.117705},
url = {https://doi.org/10.7759/cureus.117705}
}RIS
TY - JOUR TI - Sequential Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapy and Late-Line Tucatinib in Patients With HER2-Positive Breast Cancer and Brain Metastases: A Real-World Case Report. AU - Thakur P AU - Gupta M AU - Kant LC AU - Mehta P AU - Thummar V PY - 2026 JO - Cureus DO - 10.7759/cureus.117705 UR - https://doi.org/10.7759/cureus.117705 ER -
APA
P, T., M, G., LC, K., P, M., & V, T. (2026). Sequential Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapy and Late-Line Tucatinib in Patients With HER2-Positive Breast Cancer and Brain Metastases: A Real-World Case Report.. Cureus. https://doi.org/10.7759/cureus.117705
Source records
- pubmed · retrieved 2026-11-10T19:03:46.689Z